PCR Perspectives

Hector Garcia joins Salvatore Brugaletta in a discussion on the concept of vulnerable plaque, a key topic in contemporary cardiology. Together, they review the well-established definition of vulnerable plaque, characterised by high-risk features that predispose to rupture and cardiovascular events, and explore how advances in invasive and non-invasive imaging allow clinicians to identify these lesions in practice. The discussion also addresses the ongoing challenge of determining the best management strategy, emphasising the importance of treating not only the plaque but the overall vulnerable patient, while awaiting results from ongoing trials on potential focal therapies. Hosted on Acast. See acast.com/privacy for more information.

Javier Escaned and Niels Van Royen explore the evolving role of physiology in coronary assessment, with a focus on angiography-derived and imaging-derived indices, highlighting the growing potential of AI-driven tools to integrate anatomical and functional data, enabling more comprehensive and flexible decision-making without the need for pressure wires.While these technologies offer significant advantages, including real-time guidance and improved lesion localisation, challenges remain regarding heterogeneity between systems and the need for robust clinical validation. The conversation also addresses the complementary role of OCT-derived physiology and the ongoing challenges in diagnosing and managing microvascular dysfunction, underscoring the complexity and rapid evolution of the field. Hosted on Acast. See acast.com/privacy for more information.

Nina Van Der Hoeven meets Roxana Mehran, winner of the Andreas Grüntzig Ethica Award 2026, the highest distinction in interventional cardiology.At this stage of her career, after major contributions to clinical trials, guidelines, and the field at large, Roxana Mehran reflects on her journey. What is she most proud of? How does she view clinical research today? And what key lessons has she learned along the way?In this exclusive #europcr 2026 interview, she shares her experiences, insights, and personal reflections, while also discussing the initiatives she has led since the beginning of her career to promote women in interventional cardiology.She also addresses the challenges that remain, and what still needs to be done to support and encourage more women to enter and progress in the field. Through her perspective, she reaffirms her commitment to reducing the persistent gender gap and continuing the mission she has set for herself.A conversation that highlights both a remarkable career and a continuing drive to reshape the future of the field. Hosted on Acast. See acast.com/privacy for more information.

Major LBT from EuroPCR 2026This major late-breaking trial from #EuroPCR 2026 presents a landmark patient-level meta-analysis comparing PCI with drug-eluting stents (DES) versus CABG for left main coronary artery disease. Combining long-term data from the EXCEL, NOBLE, PRECOMBAT, and SYNTAX trials, the analysis found remarkably similar mortality outcomes between the two strategies at both 5 and 10 years. David Hildick-Smith and Brian Bergmark discuss how these findings challenge traditional assumptions about the long-term survival advantage of surgery and what they mean for heart team decision-making. Hosted on Acast. See acast.com/privacy for more information.

Major LBTs from EuroPCR 2026How should coronary artery disease (CAD) be managed in patients undergoing TAVI?At #europcr 2026, Martin Leon and Roberto Scarsini discuss the findings of a patient-level meta-analysis pooling data from four randomised trials: ACTIVATION, NOTION-3, FAITAVI, and TCW.The analysis included 1,050 patients with severe aortic stenosis and concomitant CAD, comparing medical therapy, angiography-guided PCI, and FFR-guided PCI strategies.At 1 year, PCI was associated with a lower rate of MACE compared with conservative management.Among the different strategies, FFR-guided PCI showed the greatest benefit, reinforcing the value of physiological assessment when treating these complex patients.Beyond the trial results, the conversation moves toward a practical algorithm for approaching severe AS and CAD, and raises important questions about when, how, and in whom revascularisation should really be performed.Listen to the full discussion to learn more about the implications of these findings for clinical practice. Hosted on Acast. See acast.com/privacy for more information.

This major late-breaking trial from #EuroPCR 2026 highlights new insights from the CHAMPION AF study, one of the largest randomised trials comparing left atrial appendage closure (LAAC) with direct oral anticoagulants (DOACs) in patients with atrial fibrillation. In this interview, Philippe Garot and Jens Erik Nielsen-Kudsk discuss the pre-specified age subgroup analysis, showing consistent efficacy across younger and older populations, with significantly lower bleeding rates in the LAAC arm and very high procedural safety. They also explore how these findings could influence future patient selection and expand the role of LAAC in stroke prevention strategies for AF patients. Hosted on Acast. See acast.com/privacy for more information.

Chronic total occlusions (CTOs) remain a key area of uncertainty in interventional cardiology, particularly regarding symptom improvement after PCI.In this EuroPCR 2026 interview, John Davies and Sarosh Khan discuss the ORBITA CTO trial and its implications for clinical practice.As the first double-blind, placebo-controlled randomised trial in CTO PCI, ORBITA CTO evaluates whether symptom relief, especially angina frequency, truly exceeds placebo in carefully selected patients.The discussion highlights the study’s design, key findings, and what they mean for CTO operators and clinicians managing patients with CTOs in everyday practice. Hosted on Acast. See acast.com/privacy for more information.

In this podcast episode, Frédéric Bouisset and Louis-Marie Desroche explore why mastering AI prompting is becoming a key clinical skill for interventional cardiologists. From setting clear objectives to providing the right context and double-checking the outputs, discover the three essential pillars to get reliable and meaningful answers from AI. Hosted on Acast. See acast.com/privacy for more information.

In this podcast episode, Juan Granada, Michael Borger and Joao Cavalcante highlight that aortic insufficiency differs from aortic stenosis and is often underestimated. Early, comprehensive evaluation and imaging are crucial. Surgery is standard for severe cases, while TAVI with dedicated devices is an option for high-risk patients. Hosted on Acast. See acast.com/privacy for more information.

Joanna Wykrzykowska and Hélène Eltchaninoff discuss challenges in treating patients with small aortic annuli, which are common, especially in women, and present risks such as higher gradients, coronary occlusion, pacemaker need, and paravalvular leak. Valve selection and positioning are critical, balancing hemodynamics and complication avoidance. Hosted on Acast. See acast.com/privacy for more information.

Azeem Latib and Giuseppe Tarantini discuss how transcatheter therapies are increasingly used to treat critically ill patients with severe valvular disease and cardiogenic shock—patients once considered untreatable. They highlight cases ranging from severe AS with ACS to acute papillary muscle rupture and acute severe regurgitation, showing how TAVI, balloon valvuloplasty and mechanical support can stabilise or even definitively treat these high-risk patients. Above all, they stress the need for a true multidisciplinary Heart Team to manage these complex situations and offer life-saving options where none existed before. Hosted on Acast. See acast.com/privacy for more information.

Nina Wunderlich and Patrick Calvert discuss mitral paravalvular leaks, which are relatively common. Percutaneous closure is now the default approach, and imaging is central to success: detailed pre-procedural assessment, 3D TOE during the procedure, and careful planning of transseptal puncture.  Hosted on Acast. See acast.com/privacy for more information.

Fabien Praz and Neil Fam talk about the management of patients with combined mitral and tricuspid regurgitation, who are often elderly with heart failure and multiple comorbidities. Careful assessment—including echocardiography, hemodynamics, and sometimes CT—is crucial to identify the dominant lesion. Surgery is preferred if feasible, but for high-risk patients, transcatheter repair or replacement is considered. Hosted on Acast. See acast.com/privacy for more information.

Bernard Prendergast and Fabien Praz discuss updates from the new ESC/EACTS guidelines on aortic stenosis. Key changes include expanding TAVI to patients aged 70 and older, supporting early intervention in asymptomatic patients, and providing guidance for bicuspid aortic valves. These updates emphasise shared decision-making, careful patient selection, and lifetime management strategies. Hosted on Acast. See acast.com/privacy for more information.

Lukas Stolz and Rebecca Hahn discuss advances in transcatheter tricuspid valve intervention, emphasising that reducing tricuspid regurgitation (TR) to mild levels is key for improving patient outcomes, including mortality and heart failure hospitalisations. Decision-making between transcatheter edge-to-edge repair (T-TEER) and transcatheter tricuspid valve replacement (TTVR) depends on anatomy, imaging, and patient factors like pacemakers or bleeding risk. Hosted on Acast. See acast.com/privacy for more information.

Philipp Lurz and Saibal Kar discuss iatrogenic atrial septal defects from transseptal procedures. Small ones usually close on their own, while large defects causing significant shunting need closure to prevent right heart overload. Some moderate defects may be beneficial by decompressing the left atrium, so closure isn’t always needed. With the increasing amount of procedures, understanding the hemodynamics is also key to safe management. Hosted on Acast. See acast.com/privacy for more information.

Tiffany Patterson and Davide Capodanno address the increasingly common scenario of managing coronary artery disease (CAD) in patients undergoing TAVI. With up to half of TAVI candidates presenting with CAD, they highlight new evidence from NOTION-3 showing that revascularization reduces major adverse cardiac events. The takeaway: CAD in TAVI patients matters, should be assessed thoughtfully, and evidence is evolving to guide both lesion selection and timing. Hosted on Acast. See acast.com/privacy for more information.

Francesco Maisano interviews Michael Borger, co-chair of the 2025 ESC/EACS valvular heart disease guidelines, on their practical impact. The updated guidelines emphasize earlier intervention in primary mitral regurgitation, especially for asymptomatic patients with risk factors, while surgery remains preferred for low-risk patients. Michael Borger stresses the importance of a multidisciplinary team approach, high-volume centres for complex cases, and timely, evidence-based interventions to improve patient outcomes. Hosted on Acast. See acast.com/privacy for more information.

Lorenz Räber and Kasper Korsholm highlight why pre-procedural imaging—particularly cardiac CT—has become essential for successful left atrial appendage occlusion (LAAO). They explain that the LAA is highly variable between patients, making detailed planning crucial for safety, device selection, and optimal procedural results. Hosted on Acast. See acast.com/privacy for more information.

Michael Joner and Francesco Saia discuss the newly developed D-PACE Score, a tool designed to predict delayed AV block occurring more than 24 hours after TAVI—an unmet clinical need given that current risk models focus mainly on early events. The next steps aim to refine the algorithm and integrate it into standardized pathways for conduction-disturbance management after TAVI. Hosted on Acast. See acast.com/privacy for more information.

In this #pcrlv2025 conversation, Ellen Ross and Marta Sitges discuss the recent initiative from Global Heart Hub, a patient association: an in-depth look at the situation of women living with heart valve disease, the gaps identified, and the call to action that followed.They reflect on what these specific needs are, why they’re often overlooked, and how clinicians can adapt their approach to offer more meaningful support to women throughout their journey.Hit play to hear their perspectives and understand what can truly move the needle in daily practice. Hosted on Acast. See acast.com/privacy for more information.

Listen to this PCR London Valves 2025 interview with Philippe Généreux and Philippe Pibarot, who explore the 7-year results of PARTNER 3 in low-risk patients.They walk through the main findings of this TAVR versus SAVR comparison in symptomatic severe aortic stenosis (AS). At 7 years, the primary endpoint — the composite of mortality, stroke and rehospitalisation — shows similar rates between both strategies.The conversation then turns to valve durability and whether the early promises of TAVR are being fulfilled when compared with surgery, what still needs to be improved on each side, and how these long-term data might influence clinical practice now that two strong options exist for low-risk patients.They conclude by highlighting how Heart Team discussions will become even more crucial in this context.Curious to learn more? Hit play! Hosted on Acast. See acast.com/privacy for more information.

While the PCR London Valves 2025 Course is underway, Francesco Maisano and Fabien Praz discuss how the latest ESC/EACTS valvular guidelines affect clinical practice. What’s changing in surgery? How do repair and replacement strategies differ under the new recommendations, and what’s the impact on transcatheter interventions? Discover key insights from this exclusive interview: watch the whole exchange now! Hosted on Acast. See acast.com/privacy for more information.

What makes TAVI in bicuspid aortic valve disease so challenging—and how can those challenges be overcome? In this #europcr 2025 expert discussion, Chiara De Biase, Kentaro Hayashida, and Didier Tchetche share practical insights on navigating anatomical variability, refining patient selection, and optimising valve sizing. They also address the critical role of calcification and how it can influence procedural outcomes. Whether you're performing TAVI in complex cases or building your expertise, this conversation offers valuable takeaways you won’t want to miss! Hosted on Acast. See acast.com/privacy for more information.

Listen to this #europcr 2025 interview to see Giuseppe Di Gioia and Jens Flensted Lassen as they break down the essentials of the provisional strategy for non-left main true bifurcation lesions. This approach offers a stepwise and adaptable treatment path: start with one stent in the main vessel, with the option to implant a second if needed.They highlight the importance of proximal optimisation, techniques to protect the side branch, and how imaging can support each step. The discussion also touches on the potential role of drug-coated balloons to limit metal use in the bifurcation segment.Get practical tips and key considerations to make the most of this streamlined yet versatile strategy. Hosted on Acast. See acast.com/privacy for more information.

Howard Herrmann and Raj Makkar discuss valve under-expansion in the ACURATE neo2 from the IDE trial sub-study. Fluoroscopy showed about 22 % of valves were under-expanded, often linked to heavy calcium buildup. These valves had worse outcomes, including higher rates of death and stroke. What’s behind this issue, and how can it be prevented? Listen to their #europcr 2025 discussion to learn more! Hosted on Acast. See acast.com/privacy for more information.

Robert Byrne and Bruno Scheller discuss drug-coated balloon (DCB) angioplasty at #europcr 2025. Nearly 20 years after its introduction, where does DCB angioplasty stand today? When and how should it be used in daily practice?Discover what defines adequate lesion preparation for a DCB strategy in de novo disease, the role of intravascular imaging in deciding when to use DCB, and best practices for managing dissections.Plus, get insights on upcoming data and the future of drug-coated balloon angioplasty.Listen to this episode to get all the answers! Hosted on Acast. See acast.com/privacy for more information.

In this #europcr 2025 interview, Tanja Rudolph, Dan Blackman, and Radoslaw Parma explore the crucial aspects of repeat transcatheter valve replacement. They dive into the risks of coronary obstruction, the importance of preserving coronary access, and strategies to optimise hemodynamics despite higher residual gradients. The discussion also covers how the index TAVR device impacts outcomes and why CT screening is essential in planning. Tune in to get a clear picture of the current evidence and what new data is just around the corner. Hosted on Acast. See acast.com/privacy for more information.

Tiffany Patterson, Nicolas Van Mieghem, and Philippe Généreux reveal the hottest emerging TAVI indications for 2025 in this #europcr 2025 discussion.They review key trials on asymptomatic severe aortic stenosis—RECOVERY, AVATAR, ONLY TAVR, and EVoLVeD—which show early TAVI or surgery reduces hospitalisations for heart failure and suggests lower mortality and stroke compared to clinical surveillance. The discussion then moves to symptomatic moderate aortic stenosis, highlighting the recent TAVR UNLOAD study in heart failure patients with reduced ejection fraction.They also touch on the PROGRESS and EXPAND II trials, and share early insights on new devices for aortic regurgitation, now entering randomised comparisons with surgery. Listen now to stay ahead on the expanding role of TAVI. Hosted on Acast. See acast.com/privacy for more information.

When should TAVI be performed—and how should coronary disease be managed in these patients?Liesbeth Rosseel, Davide Capodanno, and Michael Joner explore two key questions shaping the future of TAVI. They highlight findings from the EARLY-TAVI trial, which shows that early intervention in asymptomatic patients with severe aortic stenosis significantly reduces rehospitalisation. Then, they turn to the NOTION-3 trial, comparing PCI vs medical therapy for CAD prior to TAVI—revealing a benefit in reducing MACE, though at the cost of increased bleeding.The message is clear: earlier may be better, and managing CAD is increasingly important in the TAVI landscape.Hear what could reshape tomorrow’s practice! Hosted on Acast. See acast.com/privacy for more information.

Simon Redwood interviews John Forrest, principal investigator of the Evolut Low Risk Bicuspid Study, during #europcr 2025. As TAVR moves into younger patients—many with bicuspid valves—questions remain about how well the procedure performs in this anatomy, which was excluded from earlier trials. In this exchange, they review the study design, patient selection, and main outcomes, and compare results with the original Evolut Low Risk study. The performance of the Evolut platform in bicuspid valves may even prove superior to tricuspid cases—though long-term follow-up is essential. Valve thrombosis is also on the table. Listen to this episode now to explore the current data and what’s still to come! Hosted on Acast. See acast.com/privacy for more information.

What’s the best approach for STEMI patients with multivessel disease? Angela Mcinerney, Natalia Pinilla, and Matthias Götberg share their perspectives on how practice has evolved, with a focus on the COMPLETE trial and its intracoronary imaging substudy.They discuss what imaging reveals about non-culprit lesions, how it may influence treatment, and how these insights are applied in daily cathlab workflows. The conversation also touches on expectations from the upcoming COMPLETE-2 trial.Listen now for expert views on a common but complex cathlab scenario. Hosted on Acast. See acast.com/privacy for more information.

In this #europcr 2025 interview, Davide Capodanno and Woong Chol Kang explore the latest insights from the 4D-ACS trial and what it could mean for antithrombotic therapy in patients with acute coronary syndrome. They discuss who was included in the trial and walk through the two de-escalation strategies that were tested: reducing the number of the drugs, from dual antiplatelet therapy to single antiplatelet therapy, and lowering the prasugrel dose from 10 mg to 5 mg. Finally, they highlight the key findings that could help refine clinical practice. Listen now to get up to speed in just a few minutes. Hosted on Acast. See acast.com/privacy for more information.

In this #europcr 2025 video, Nicola Ryan speaks with Dejan Milasinovic about when and how to adopt an upfront two-stent strategy in bifurcation PCI. The key is assessing the side branch: if stenosis is high-grade and disease is extensive, treatment may be needed from the start—using POBA, a DCB, or a second stent. Anatomy should guide the choice between a provisional or two-stent approach. Intracoronary imaging is essential to detect issues like abluminal rewiring and stent distortion, especially when treating the side branch. As highlighted by the OCTOBER trial, proper rewiring and final stent architecture are crucial to reduce the risk of long-term complications.Find out how to tailor your approach to each bifurcation scenario. Hosted on Acast. See acast.com/privacy for more information.

In this #europcr 2025 discussion, Mayra Guerrero, Thomas Modine, and Philipp Lurz share their views on the evolving landscape of mitral valve treatment. While transcatheter edge-to-edge repair (TEER) remains a safe and effective approach, it doesn’t work for every patient. That’s why alternatives like TMVR, annuloplasty, or NeoChords—all currently under investigation—are generating attention.The field is moving toward transseptal, transcatheter options that may deliver better reduction of mitral regurgitation, along with improved symptoms and quality of life. They offer the added advantage of allowing future valve-in-valve procedures if needed.Should a strong mitral program combine both repair and replacement? How do we decide between the two?There are still challenges—but innovation is pushing the field forward.Listen now and get a glimpse of what’s next for mitral therapies! Hosted on Acast. See acast.com/privacy for more information.

Calcified bifurcation lesions remain one of the toughest challenges in interventional cardiology, combining two high-risk features into one complex scenario. In this #europcr 2025 interview, Dejan Milasinovic, Miroslaw Ferenc, and Mohamed Abdel Wahab explore why this topic deserves special attention.They break down how intra-coronary imaging can guide the approach, help tailor strategy, and ultimately improve outcomes. Discover how to move beyond anatomy alone - by factoring in the patient’s clinical profile and procedural context - to find a strategy that’s not only effective, but also simple and safe.Listen to this eppisode now to sharpen your approach to one of the most demanding lesion subsets in daily practice. Hosted on Acast. See acast.com/privacy for more information.

How effective is cerebral protection during TAVI?Bernard Prendergast and Rajesh Kharbanda take a deep dive into this key procedural question, reviewing the latest evidence from two major randomised trials—PROTECTED TAVR and BHF PROTECT-TAVI.Although both studies individually failed to demonstrate a clinical benefit for cerebral protection devices, a new patient-level meta-analysis presented at #EuroPCR2025 offers fresh insights.Listen to this episode now to understand how aligning endpoints and patient profiles has helped uncover new signals that could shape future practice. Hosted on Acast. See acast.com/privacy for more information.

In this exchange, Vijay Kunadian and Javier Escaned explore the real-world implementation of INOCA (Ischemia with Non-Obstructive Coronary Arteries) and ANOCA (Angina with Non-Obstructive Coronary Arteries) diagnostic pathways. Drawing on the 2024 CCS (Chronic Coronary Syndromes) guidelines, and the EAPCI consensus document, they discuss why these conditions remain underdiagnosed—and how structured invasive assessment can make a difference, even in time-constrained clinical environments.This conversation offers practical insights for improving patient care by refining diagnosis and treatment strategies in cases where traditional imaging may fall short. Hosted on Acast. See acast.com/privacy for more information.

At #EuroPCR2025, Martine Gilard, Antonio Mangieri, and Marco Barbanti share their perspectives on managing coronary artery disease in patients scheduled for TAVI. Is coronary angiography always necessary? When should PCI be performed—before, during, or after the procedure? And how do you decide? Tune in for a practical exchange on strategy, timing, and patient selection! Hosted on Acast. See acast.com/privacy for more information.

Nicola Ryan and Flavio Ribichini discuss the challenges of treating the calcified left main stem. They break down the complexities of this high-risk condition and highlight the role of mechanical circulatory support in everyday practice. They focus on the role of intracoronary imaging as a game-changer and examine the use of one versus two stents, outlining cases where two stents may be necessary.Key takeaways1. Calcified left main stem disease is complex but can be simplified with the right tools.2. Intravascular imaging is crucial for accurate assessment and treatment planning.3. A careful, step-by-step approach leads to the best angiographic results. Hosted on Acast. See acast.com/privacy for more information.

What does the PREVENT trial tell us about managing vulnerable plaques? Recorded during #europcr 2025, this discussion features Michael Haude and Thomas Cuisset as they review key insights from this major study of over 1,600 patients with physiologically non-significant but vulnerable plaques identified by intracoronary imaging—mainly IVUS. Patients were randomised to receive either optimal medical therapy (OMT) alone or combined with preventive PCI, and followed over several years. While the composite endpoint favored the PCI group, the benefit was driven solely by a reduction in target lesion revascularisation—without differences in death or myocardial infarction. Should PCI be systematically performed in such cases? Tune in for a nuanced expert perspective! Hosted on Acast. See acast.com/privacy for more information.

Stephan Windecker and Flavio Ribichini review the outcomes of the FAITAVI trial, presented during the #europcr 2025 LBT session.As coronary artery disease is the most common cardiac comorbidity in patients undergoing TAVI, the trial set out to evaluate whether physiology-guided decision-making could offer better clarity.When performing diagnostic angiography before TAVI, clinicians often find intermediate coronary lesions that don’t obviously require revascularisation — so what's the right strategy in these cases?FAITAVI is the first randomised trial comparing angiography-guided versus FFR-guided PCI decisions in the TAVI setting. Learn more about the study design, inspired by FAME-1, and how the results support the feasibility and value of FFR measurements in patients with CAD undergoing TAVI. The data also confirm that intermediate lesions can safely be left untreated.Listen to this episode now to understand how these findings could change practice! Hosted on Acast. See acast.com/privacy for more information.

Cleverson Zukowski and Pablo Lamelas take a moment during #europcr 2025 to shed light on a major regional milestone: the first-ever guidelines for the treatment of left main disease, issued jointly by the Latin American Society of Interventional Cardiology (SOLACI) and the Interamerican Society of Cardiology (SIAC). Why were these guidelines created specifically for Latin America? What are their key recommendations? And how can they be applied in day-to-day practice, especially when deciding between PCI and surgery?Tune in to hear how these guidelines reflect the region’s unique healthcare challenges and may help tailor treatment to the specific needs of Latin American patients. Hosted on Acast. See acast.com/privacy for more information.

In this #europcr 2025 exchange, Ole De Backer and Philippe Garot explore the evolving landscape of transcatheter left atrial appendage (LAA) occlusion. From differences in patient selection on either side of the Atlantic—high bleeding risk in Europe vs. broader indications in the US—to upcoming pivotal trials comparing LAA closure to DOACs, this conversation covers it all.They also break down what defines a state-of-the-art LAA procedure, with an emphasis on pre-procedural imaging (cardiac CT or 3D TEE), and share key insights on post-procedural management, including antithrombotic therapy and follow-up imaging.Hit play for a quick yet comprehensive update on where LAA closure is headed. Hosted on Acast. See acast.com/privacy for more information.

Elliot Smith, Thomas Hovasse, and Roberto Garbo present a structured, step-by-step approach to chronic total occlusion (CTO) interventions, starting from angiographic analysis through to strategy selection and technique adaptation.The discussion begins with angiographic assessment, emphasising the importance of identifying key anatomical features upfront. Based on this evaluation, operators determine the most appropriate strategy—typically beginning with an antegrade approach, with readiness to escalate to retrograde or dissection techniques depending on case complexity and progression.The panel outlines essential tools for CTO procedures, including a 7 Fr guiding catheter, various wires (from soft to stiff), and microcatheters, while also addressing how these tools are introduced into routine practice. Attention is given to operator experience, decision-making flexibility, and technique sequencing.In parallel, the importance of progressive skill acquisition is highlighted. Failure is positioned not as an endpoint, but as a learning opportunity—integral to refining technique and gaining confidence.Listen to this discussion for structured guidance on navigating CTOs in a safe and effective way. Hosted on Acast. See acast.com/privacy for more information.

What is the optimal TAVI access approach in today’s practice? In this conversation at PCR London Valves 2024, Ole De Backer and Maarten Vanhaverbeke break down the latest evidence and trends in TAVI access. Listen to this podcast to learn about the dominance of transfemoral access, the role of alternative routes like transcarotid and transaxillary, the growing use of cutting-edge tools like intravascular lithotripsy and orbital atherectomy, and much more! Hosted on Acast. See acast.com/privacy for more information.

How do we navigate the thin line between bleeding risk and thrombosis in high-risk patients undergoing tricuspid valve interventions? Marianna Adamo and Fabien Praz explore the latest strategies in anticoagulation, the challenges of managing complex cases and how cutting-edge research is shaping the future of care. Listen to this podcast to discover the keys to optimizing outcomes in this rapidly evolving field! Hosted on Acast. See acast.com/privacy for more information.

Curious about the specific considerations for TAVI in women? Martine Gilard and Dan Blackman highlight the challenges women face in the diagnosis and treatment of aortic stenosis (underrepresentation, later presentation, undertreatment...) while exploring key anatomical differences (smaller aortic anatomy, less calcification...), and how these factors impact diagnostic thresholds, imaging and valve selection. Hosted on Acast. See acast.com/privacy for more information.

Wondering which is the better option for female patients—SAVR or TAVR? Don’t miss this exchange between Hendrik Treede and Hélène Eltchaninoff. They explore the unique challenges and nuances of valve interventions for women, highlighting evolving strategies to optimize treatment and improve outcomes. Hosted on Acast. See acast.com/privacy for more information.

Curious about the latest advancements in transcatheter tricuspid valve interventions? Don't miss this discussion between Philipp Lurz and Lukas Stolz at PCR London Valves 2024! They delve into the topic of residual tricuspid regurgitation after transcatheter repair—a challenge that still needs improvement despite significant progress. Hosted on Acast. See acast.com/privacy for more information.